Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed 1 min ago
News

STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more

Why it’s here: This is a multi-story pharma newsletter digest; however it includes policy-relevant items (House China committee probe of pharma trial sites in Xinjiang and FDA action against J&J) in the biotechnology area, so it is partially relevant but the roundup format is a rejection factor.

Trace across the board

Item

  1. 2d agoSTATSTAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and moreThis STAT Pharmalittle roundup notes that major pharmaceutical firms are using AI for molecule design and early-stage work, and that several large drugmakers pledged to the House China committee to avoid new Xinjiang and military-affiliated trial sites.
    2 articles
    1. 2d agoSTATSTAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
    2. 2d agoSTATEarliestSTAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
    Biotech17 linked

Coverage

1 outlets · first seen 2d ago

Connected

6 links

About

  • House China committee
  • Merck
  • artificial intelligence

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy